Hsp40 Antibody (OASE00413)
- Known as:
- Hsp40 Antibody (OASE00413)
- Catalog number:
- oase00413
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- Hsp40 Antibody (OASE00413)
Related genes to: Hsp40 Antibody (OASE00413)
- Gene:
- DNAJB1 NIH gene
- Name:
- DnaJ heat shock protein family (Hsp40) member B1
- Previous symbol:
- HSPF1
- Synonyms:
- Hsp40, Sis1, RSPH16B
- Chromosome:
- 19p13.12
- Locus Type:
- gene with protein product
- Date approved:
- 1996-10-02
- Date modifiied:
- 2015-11-19
Related products to: Hsp40 Antibody (OASE00413)
Related articles to: Hsp40 Antibody (OASE00413)
- Hydrogen-deuterium exchange (HDX) of protein backbone amides provides a powerful probe of conformational dynamics. However, when experiments are performed in HO/DO mixtures, quantitative interpretation is hindered by back exchange and isotope effects not captured by the classical Linderstro̷m-Lang (LL) model. We introduce a generalized Linderstro̷m-Lang (GLL) framework that explicitly accounts for forward and reverse exchange and for changes in protection upon isotopic substitution. Analytical solutions describe equilibrium enrichment (fractionation) and protection factors in mixtures, reducing to the LL model in pure DO. Application to HDX/NMR of the molecular chaperone DNAJB1 in 50% DO demonstrates that the GLL model recovers protection factors at 100% DO. Ignoring back exchange (i.e., using the LL model), protection factors are systematically underestimated. A particularly powerful feature of our approach is that a single HDX experiment in a mixture (e.g., 50% DO) simultaneously provides protection factors that report on conformational dynamics and local stability and fractionation factors that are sensitive to the local hydrogen-bonding environment. - Source: PubMed
Publication date: 2026/03/17
Grimaldi AntonioHobbs BillyStofella MicheleKaramanos Theodoros KPaci Emanuele - Carney complex is a rare multiple neoplasia syndrome caused primarily by inactivating variants in the PRKAR1A gene, which encodes the regulatory subunit type I alpha of protein kinase A. Although classically associated with myxomas, lentigines, and endocrine tumors, the full tumor spectrum related to PRKAR1A loss of function is not completely defined. Here, we report a patient with a molecularly confirmed diagnosis of Carney complex carrying a de novo PRKAR1A (NM_002734.5):c.348+1G>A splice-site variant. In addition to typical manifestations, the patient developed two uncommon malignancies: invasive breast carcinoma (luminal B-like) at a young age and fibrolamellar hepatocellular carcinoma lacking the DNAJB1-PRKACA fusion typically found in sporadic cases. The coexistence of these two rare tumors in a single carrier of a pathogenic PRKAR1A variant expands the phenotypic variability associated with this condition and supports the possibility that PRKAR1A loss contributes to oncogenesis beyond the classical endocrine and mesenchymal tissues. This Data Report provides clinically relevant documentation of an unusual tumor presentation associated with a pathogenic PRKAR1A variant and underscores the importance of ongoing clinical surveillance in affected individuals. - Source: PubMed
Publication date: 2026/05/28
Colares Perez Abílio AlonsoPinheiro Correia LauraPonte Conrado RégisMalheiro Vinícius NascimentoHirth Carlos GustavoMagno Cavalcante Diane IsabelleRêgo Coelho GustavoPinto Quidute Ana RosaCalheiros Campelo Maia Danielle - The integrated stress response (ISR) can cause high-grade serous ovarian cancer (HGSOC) cells to arrest in G1 phase, significantly suppressing their hyperproliferation. Nevertheless, the specific molecular mechanisms of the ISR in HGSOC remain unclear. - Source: PubMed
Publication date: 2026/05/05
Li QianKong FanqiangCui PenghuaGao XiujuanZhuang XinrongZhang ZhongkaiTian TianZhang Guixiang - Fibrolamellar hepatocellular carcinoma (FLC) is a rare and distinct histologic subtype of hepatocellular carcinoma that typically arises in non-cirrhotic livers of adolescents and young adults without underlying viral hepatitis or chronic liver disease. Accounting for less than 1% of all primary liver cancers, FLC is characterized by unique clinical, radiologic, and molecular features, most notably the highly characteristic fusion. Due to its rarity and frequently nonspecific presentation, diagnosis is often delayed or misinterpreted as by benign hepatic lesions such as focal nodular hyperplasia or adenoma. This report presents a rare case of metastatic FLC in a young adult who initially presented with right upper quadrant pain, anemia, and preserved hepatic function. Imaging revealed a large hepatic mass with a central non-enhancing area suggestive of necrosis, and histopathologic evaluation aided in the diagnosis based on characteristic lamellar fibrosis, polygonal eosinophilic cells, and positive CK7 and HepPar-1 staining. Confirmatory molecular testing through fusion was not performed. Planned treatment with a combination regimen of nivolumab and neratinib was scheduled; however, the patient deteriorated rapidly, and systemic therapy could not be initiated before death. Through this case and accompanying review, we aim to highlight the diagnostic complexity, molecular underpinnings, and current therapeutic approaches of FLC. This case was notable for advanced peritoneal carcinomatosis at presentation, severe thrombocytosis, and the diagnostic and therapeutic challenges posed by metastatic fibrolamellar carcinoma without molecular confirmation. Taken together, this underscores the importance of early recognition, molecular testing, and coordinated clinical management in optimizing outcomes for this uncommon malignancy. - Source: PubMed
Publication date: 2026/05/06
El Darzi RoyAshy ChristopherKhrayzat AliChahine SallyTawil AymanTemraz Sally - Vosamidines A-C (-), three polycyclic 2-aminoimidazole alkaloids, were isolated from a marine calcareous sponge, . Their structures were determined by extensive analysis of spectroscopic and spectrometric data, along with ECD computational studies. Vosamidine A possesses a 6/5/5/5/6/15(6)(5)-fused ring system based on a unique pentacyclic core. Vosamidine B is an oxidized and ring rearranged derivative of . Vosamidine C possesses an unusual 5/5/6/5/5/8 hexacyclic ring system incorporating a thioether ring. Plausible biosynthetic pathways for - are proposed. Compounds and had modest inhibition in the oncogenic fusion protein kinase DNAJB1-PKAcα assay. - Source: PubMed
Publication date: 2026/04/22
Senadeera Sarath P DWang DongdongWilson Brice A PSmith Emily ALeal Camille VZhang PingO'Keefe Barry RCarroll Anthony RBeutler John A